Will Boston Scientific stock avoid deeper losses after enroute TCAR System recall increases compliance risk?

Traders Union
All News
Stocks
Boston Scientific falls 3.33% to $48.2

Highlights

Boston Scientific reported an August 25 cybersecurity incident that disrupted global operations and restricted order processing and shipments.
A recall of Enroute TCAR System catheters has imposed new compliance demands and introduced additional reputational risk.
Shares of Boston Scientific dropped 3.33% to $48.2, trading below key moving averages with momentum and trend signals indicating strong bearish control and a projected range of $46.74 to $49.66 over the next 2 to 3 days.

Cyber incident and product recall disrupt operations and escalate risks

Boston Scientific disclosed a cybersecurity incident on August 25 that has disrupted its global operations, including its ability to process and ship orders, according to Thenextweb and Breakingthenews. Operational bottlenecks from this event have introduced significant challenges to revenue flow and delivery commitments, weighing on short-term business continuity. In addition, a product recall involving Enroute TCAR System percutaneous catheters, as reported by Seekingalpha, has introduced further compliance obligations and reputational risks.

Downtrend momentum confirmed as indicators flag persistent weakness

On the technical front, BSX is trading below the MA-20 at $49.59 and the MA-50 at $50.53 on the 1-hour chart, with the price well under the MA-200 at $68.94 on the daily timeframe. The Ichimoku Kijun at $48.95 serves as immediate resistance. Momentum indicators are negative: MACD signals strong sell, ADX confirms a persistent downtrend, and Bull/Bear Power indicates solid seller dominance. RSI is at 33.07, while Stochastic RSI and CCI both point to oversold conditions. The Awesome Oscillator is neutral and does not reinforce the current trend.

Downside risks prevail amid strong resistance and limited rebound potential

Over the next 2–3 days, the expected price range for BSX is $46.74 to $49.66. The probability of further downside movement is high, while the chances of a rebound remain low in the current structure. The base scenario is a continuation within a sideways corridor between identified support and resistance levels. If the price manages to break above the $48.95 resistance, a short-term rebound could unfold, but sustained pressure below $46.74 may lead to additional declines.

Anton Kharitonov, expert at Traders Union, sees a predominantly negative setup for Boston Scientific. He believes recent operational disruptions — including the cybersecurity incident and product recall — amplify downside risks. Technical signals confirm persistent selling and fragile sentiment, with the price trading below all key moving averages. "Until $48.95 is reclaimed, I remain cautious and expect continued pressure on BSX."

Earlier, analysts noted that Boston Scientific faced sustained bearish pressure as technical weakness dominated its outlook following a significant cybersecurity incident. The current analysis strengthens this view, highlighting that downside risk remains elevated, with traders advised to closely monitor the $46.74 support level and be alert to further declines if it is breached.

Source of Data: BSX Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.